Nothing Special   »   [go: up one dir, main page]

BR112014012815A2 - derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença - Google Patents

derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença

Info

Publication number
BR112014012815A2
BR112014012815A2 BR112014012815A BR112014012815A BR112014012815A2 BR 112014012815 A2 BR112014012815 A2 BR 112014012815A2 BR 112014012815 A BR112014012815 A BR 112014012815A BR 112014012815 A BR112014012815 A BR 112014012815A BR 112014012815 A2 BR112014012815 A2 BR 112014012815A2
Authority
BR
Brazil
Prior art keywords
treatment
oxadiazole derivatives
disease
trifluoromethyl oxadiazole
trifluoromethyl
Prior art date
Application number
BR112014012815A
Other languages
English (en)
Other versions
BR112014012815A8 (pt
Inventor
Hebach Christina
Nozulak Joachim
Kallen Joerg
Widler Leo
Tintelnot-Blomley Marina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014012815A2 publication Critical patent/BR112014012815A2/pt
Publication of BR112014012815A8 publication Critical patent/BR112014012815A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença". a presente invenção refere-se a novos derivados de trifluormetil-oxadiazol de fórmula (i), e sais farmaceuticamente aceitáveis dos mesmos, onde todas as variáveis são conforme definidas no relatório, composições farmacêuticas dos mesmos, combinações farmacêuticas dos mesmos, e seu uso como medicamentos, particularmente para o tratamento de neurodegeneração, atrofia muscular ou diabetes/síndrome metabólica via inibição de hdac4.
BR112014012815A 2011-11-28 2012-11-26 derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença BR112014012815A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564031P 2011-11-28 2011-11-28
PCT/IB2012/056739 WO2013080120A1 (en) 2011-11-28 2012-11-26 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Publications (2)

Publication Number Publication Date
BR112014012815A2 true BR112014012815A2 (pt) 2017-06-13
BR112014012815A8 BR112014012815A8 (pt) 2017-06-20

Family

ID=47428783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012815A BR112014012815A8 (pt) 2011-11-28 2012-11-26 derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença

Country Status (11)

Country Link
US (1) US9670193B2 (pt)
EP (1) EP2785713B1 (pt)
JP (1) JP5966014B2 (pt)
KR (1) KR20140097459A (pt)
AU (1) AU2012345557A1 (pt)
BR (1) BR112014012815A8 (pt)
CA (1) CA2856334A1 (pt)
EA (1) EA201491060A1 (pt)
ES (1) ES2606630T3 (pt)
MX (1) MX2014006409A (pt)
WO (1) WO2013080120A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008162A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP6473152B2 (ja) 2013-11-20 2019-02-20 オハイオ・ステイト・イノベーション・ファウンデーション がん関連悪液質を抑制するためのｈｄａｃ阻害剤
DK3071196T3 (da) * 2013-11-20 2019-07-01 Ohio State Innovation Foundation HDAC-inhibitorer til undertrykkelse af cancerforbundet kakeksi
WO2015185485A1 (en) 2014-06-06 2015-12-10 Basf Se Use of substituted oxadiazoles for combating phytopathogenic fungi
EP3187497A4 (en) * 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10053434B2 (en) 2015-05-07 2018-08-21 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
AU2016256917B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
EA033198B1 (ru) * 2015-07-17 2019-09-30 Такеда Фармасьютикал Компани Лимитед Оксадиазольные производные, пригодные в качестве ингибиторов hdac
WO2017014170A1 (ja) * 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
MX2017017090A (es) 2015-07-27 2018-12-11 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
PT3330259T (pt) * 2015-07-27 2020-09-03 Chong Kun Dang Pharmaceutical Corp Composto derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6, e composição farmacêutica que contêm o mesmo
PT3328843T (pt) 2015-07-27 2023-01-24 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
CA2994688C (en) 2015-08-04 2020-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3342772A4 (en) 2015-08-25 2019-03-27 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
PL3356358T3 (pl) 2015-10-02 2020-11-02 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
US10501425B2 (en) 2015-10-02 2019-12-10 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
JP6697074B2 (ja) 2015-10-12 2020-05-20 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
EP3165094A1 (en) 2015-11-03 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3165093A1 (en) 2015-11-05 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3167716A1 (en) 2015-11-10 2017-05-17 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3373732A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
BR112018009539B1 (pt) 2015-11-13 2022-05-24 Basf Se Uso de compostos da fórmula i, compostos, mistura, composição agroquímica, uso dos compostos e método para combater fungos nocivos fitopatogênicos
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
WO2017085100A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
BR112018011053A2 (pt) 2015-12-02 2018-11-21 Syngenta Participations Ag derivados de oxadiazol microbiocidas
CA3003952A1 (en) 2015-12-03 2017-06-08 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
HUE055031T2 (hu) * 2015-12-10 2021-10-28 Ptc Therapeutics Inc Módszerek Huntington-kór kezelésére
UY37062A (es) 2016-01-08 2017-08-31 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
WO2017162868A1 (en) 2016-03-24 2017-09-28 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3442951A1 (en) 2016-04-11 2019-02-20 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2018177894A1 (en) 2017-03-31 2018-10-04 Syngenta Participations Ag Fungicidal compositions
TW202334101A (zh) * 2017-04-06 2023-09-01 美商富曼西公司 殺真菌之噁二唑
EA201992878A1 (ru) 2017-06-05 2020-05-08 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни хантингтона
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
TW201910328A (zh) 2017-07-31 2019-03-16 日商武田藥品工業股份有限公司 雜環化合物
US20200339569A1 (en) * 2017-12-05 2020-10-29 Oryzon Genomics, S.A. 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EP3728244A1 (en) 2017-12-22 2020-10-28 Bayer Aktiengesellschaft Fungicidal oxadiazoles
CN111836802A (zh) 2018-02-12 2020-10-27 拜耳公司 杀真菌的*二唑
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
BR112020020663A2 (pt) 2018-04-10 2021-01-12 Bayer Aktiengesellschaft Derivados de oxadiazolina
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CN112654625B (zh) 2018-06-27 2024-08-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂环和杂芳基化合物
KR102316234B1 (ko) * 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
US20220151234A1 (en) * 2019-04-08 2022-05-19 Pi Industries Ltd. Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi
US20230079386A1 (en) 2019-05-31 2023-03-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2021014918A (es) * 2019-06-06 2022-06-27 Oryzon Genomics Sa Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6.
BR112021025300A2 (pt) 2019-06-21 2022-02-01 Bayer Ag Oxadiazóis fungicidas
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2022129190A1 (en) 2020-12-18 2022-06-23 Bayer Aktiengesellschaft (hetero)aryl substituted 1,2,4-oxadiazoles as fungicides
WO2022129188A1 (en) 2020-12-18 2022-06-23 Bayer Aktiengesellschaft 1,2,4-oxadiazol-3-yl pyrimidines as fungicides
WO2022129196A1 (en) 2020-12-18 2022-06-23 Bayer Aktiengesellschaft Heterobicycle substituted 1,2,4-oxadiazoles as fungicides
BR112023019788A2 (pt) 2021-03-30 2023-11-07 Bayer Ag 3-(hetero)aril-5-clorodifluorometil-1,2,4-oxadiazol como fungicida
BR112023019400A2 (pt) 2021-03-30 2023-12-05 Bayer Ag 3-(hetero)aril-5-clorodifluorometil-1,2,4-oxadiazol como fungicida
WO2022226388A1 (en) 2021-04-23 2022-10-27 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
JP2024519499A (ja) 2021-05-04 2024-05-14 テナヤ セラピューティクス， インコーポレイテッド 代謝疾患及びｈｆｐｅｆの治療に使用するための２－フルオロアルキル－１，３，４－オキサジアゾール－５－イル－チアゾール、ｈｄａｃ６阻害剤
UY39854A (es) 2021-07-15 2022-11-30 Kumiai Chemical Industry Co Derivado de formamida y agente de control hortícola y agrícola para el control de enfermedades de la
WO2023078807A1 (en) 2021-11-03 2023-05-11 Universität Basel A class iia hdac inhibitor and decitabine to treat myopathy
EP4295688A1 (en) 2022-09-28 2023-12-27 Bayer Aktiengesellschaft Active compound combination
WO2024068520A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068519A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068517A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068518A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024180464A1 (en) 2023-02-28 2024-09-06 Chong Kun Dang Pharmaceutical Corp. Oxadiazole derivative compounds, and the pharmaceutical composition comprising the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100107509A (ko) * 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4637843B2 (ja) 2003-05-20 2011-02-23 ノバルティス アーゲー ペルオキシソーム増殖因子活性化受容体のリガンドとしてのｎ−アシル窒素ヘテロ環
WO2005040152A1 (en) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
EP2044055A4 (en) 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
CN103221047B (zh) * 2010-01-13 2014-12-17 坦颇罗制药股份有限公司 化合物和方法
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
WO2013008162A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
BR112014012815A8 (pt) 2017-06-20
US20140329825A1 (en) 2014-11-06
JP5966014B2 (ja) 2016-08-10
US9670193B2 (en) 2017-06-06
EP2785713B1 (en) 2016-09-07
AU2012345557A1 (en) 2014-06-26
CN103998446A (zh) 2014-08-20
EP2785713A1 (en) 2014-10-08
JP2014533721A (ja) 2014-12-15
CA2856334A1 (en) 2013-06-06
KR20140097459A (ko) 2014-08-06
WO2013080120A1 (en) 2013-06-06
EA201491060A1 (ru) 2014-09-30
MX2014006409A (es) 2014-07-30
ES2606630T3 (es) 2017-03-24

Similar Documents

Publication Publication Date Title
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112014000371A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CU24117B1 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
GEP20156351B (en) Glucagon receptor modulator
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
BR112015010396A2 (pt) terapia de combinação
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
MX340985B (es) Compuestos de n-heteroarilo.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]